Entity

Time filter

Source Type

Brno, Czech Republic

Zdrahalova K.,Klinika Detske Hematologie a Onkologie | Sterba J.,Klinika detske onkologie FN | Domansky J.,Klinika detske onkologie FN | Blazek B.,Klinika detskeho lekarstvi FN | And 19 more authors.
Casopis Lekaru Ceskych | Year: 2015

Background. Acute lymphoblastic leukemia (ALL) is the most frequent childhood malignancy. Treatment has been unified in the middle of 1980 in the Czech Republic. In 2002-2007 children and adolescents with acute lymphoblastic leukemia were treated in an international randomized trial ALL-IC BFM 2002 in the Czech Republic. 291 patients aged 1-18 years were enrolled; infants below 1 year entered a separate trial. Methods and results. Patients were stratified into three risk groups according to their age, initial leukocyte count, prednisone response, presence of fusion genes BCR/ABL or MLL/ AF4, bone marrow D+15 and remission status D+33. The whole therapy took 24 months. Randomized late intensification compared standard BFM therapy with extended, usually more intensive experimental treatment. The median follow- -up was 8.7 years. Complete remission was achieved in 97.9% patients, 1% died in remission. 11% of children relapsed, 1.7% with CNS involvement. Six children (2.1%) developed secondary malignancy. Event free survival (EFS) 8 years from diagnosis was 83.5%, overall survival (OS) 91.4%. EFS and OS of the risk groups were: standard risk: 89.4%; 98.1%; intermediate risk: 82.6%; 89.6%; high risk: 68.8%; 78.1%. Male sex and age above 10 years were adverse prognostic factors. Conclusions. In comparison with the previous trial ALL-BFM 95, significant improvement was achieved. Source

Discover hidden collaborations